Clinical Trial Update: A Study to Evaluate Raptiva in Subjects With Chronic Moderate or Worse Plaque Psoriasis Who Have Had an Inadequate Response to an Anti-TNF Agent [Phase 4]

View source ↗

Summary

This document reports a Phase 4 clinical trial evaluating Raptiva (efalizumab) in adults with chronic moderate to severe plaque psoriasis who did not respond ad…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Raptiva (efalizumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Psoriasis | Phase 4 | Status: COMPLETED | Results posted: 2009-06-05